The Medicines Patent Pool (MPP) and French pharma company MedinCell (EPA: MEDCL) have signed a license agreement for a candidate long-acting drug formulation that could be used to fight malaria in low- and middle-income countries.
The license agreement relates to a three-month active injectable formulation of ivermectin using MedinCell’s BEPO technology to fight malaria transmission, and complements a collaboration between the firm and the health agency Unitaid.
"This license is key to allow rapid access to innovation for those who need it most"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze